TeamViewer AG

  • WKN: A2YN90
  • ISIN: DE000A2YN900
  • Land: Deutschland

Nachricht vom 17.10.2021 | 21:04

TeamViewer AG: TeamViewer Supervisory Board takes decisions on Executive Board

TeamViewer AG / Key word(s): Personnel
TeamViewer AG: TeamViewer Supervisory Board takes decisions on Executive Board

17-Oct-2021 / 21:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The Supervisory Board of TeamViewer today unanimously took the following decisions regarding the Executive Board:

- The contract of CEO Oliver Steil will be extended for three years until October 2024.

- Chief Financial Officer Stefan Gaiser will leave the company in mutual consent upon expiry of his current contract in 2022 after then having served as CFO for more than four years. The Supervisory Board has already initiated a structured search process to ensure a smooth transition.

- The Executive Board will be expanded by an additional member with a dedicated focus on sales and commercial excellence. The Supervisory Board will initiate the search for a suitable candidate to take on this new responsibility in the management team.

Daniel Fard-Yazdani
Head of Investor Relations 

17-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021